Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
Nonalcoholic Fatty Liver Disease (NAFLD)
Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United…
- Trial name
- NAFLD (NCT02217345)
- Testing
- Growth hormone
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Massachusetts General Hospital
Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
To rule out the beneficial effect of SGLT2-I to reduce liver fat, and change in inflammatory markers (ALT, AST) in type 2 diabetic patients with non-alcoholic fatty liver disease.
- Trial name
- NCT06668753
- Testing
- Dapagliflozin 10mg Tab or Empagliflozin 10 mg Tab
- Volunteers
- 114 people
- Sponsor
- Assiut University
Non-Alcoholic Fatty Liver Disease
Silymarin in NAFLD
This study evaluates the influence of Silymarin in reducing laboratory, ultrasonographic (Fibroscan) and metabolic components of NAFLD. Half of the patients will receive Silymarin (Verum) while the other half will receive placebo
- Trial name
- SINF (NCT02973295)
- Testing
- Silymarin
- Where
- Croatia
- Sponsor
- University Hospital Rijeka
NASH
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects
First-in-human, single centre, two parts, dose-escalation, parallel-group, safety, tolerability, pharmacokinetic and pharmacodynamic Phase I study.
- Trial name
- NCT06705998
- Testing
- BAR502 single dose, BAR502 multiple doses
- Where
- Switzerland
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- BAR Pharmaceuticals s.r.l.
NAFLD, Nonalcoholic Fatty Liver Disease
Different Exercise Modalities in the Treatment of NAFLD and Their Impact on Myokines
The goal of this 12-week clinical trial is to investigate the effectiveness of different exercise types in treating Non-Alcoholic Fatty Liver Disease (NAFLD) and to explore their impact on myokine levels associated with lipid…
- Conditions
- NAFLD, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, Fatty Liver
- Trial name
- NCT06257732
- Testing
- Exercise, Motivational Interviewing
- Where
- Turkey (Türkiye)
- Volunteers
- 144 people
- Sponsor
- Yeditepe University
Food Insecurity
Implementing Food Referrals for Equity and Sustained Health
Food insecurity (FI) disproportionately affects those who have been historically marginalized and significantly contributes to poor health outcomes.
- Trial name
- I-FRESH (NCT06661538)
- Testing
- Food Security Screening & Referral Program
- Where
- 2 sites in United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Obesity, Weight Loss
Weight Loss in Adults With Obesity Using a Combination of Low Energy Diet, Group Treatment and Intragastric Balloon
In Sweden, approximately 1.3 million adults have obesity. Obesity decreases quality of life (QoL) and increases the risk of diseases such as type 2-diabetes, non-alcoholic fatty liver disease (NAFLD), cancer and cardiovascular…
- Conditions
- Obesity, Weight Loss, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04230655
- Testing
- Low energy diet using meal replacements, CBT-based group treatment, Intragastric balloon
- Where
- Sweden
- Volunteers
- 110 people
- Sponsor
- Region Örebro County
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial
This clinical trial aims to systematically evaluate the clinical performance and accuracy of the HepaAiQ test kit, a multi-gene methylation assay based on PCR with fluorescent probe detection.
- Trial name
- NCT06842563
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Singlera Genomics Inc.
Fatty Liver Disease
Effects of Tablets of Silybum Marianum, Pueraria Lobate and Salvia Miltiorrhiza on Fatty Liver
Objectives: To examine the effects of tablets of silybum marianum, Pueraria lobate and salvia miltiorrhiza on the progression of fatty liver in patients with fatty liver.
- Trial name
- NCT05076058
- Testing
- Tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Sun Yat-sen University
Non-Alcoholic Fatty Liver Disease, Renal Transplant Complication Pre-Existing Disease
Transient Elastograghy to Detect Non Alcoholic Fatty Liver Disease in Renal Transplantation Recipients.
a. Primary (main): The presence of non alcoholic fatty liver disease in post renal transplantation recipients by non invasive methods as transient elastograghy b-Secondary (subsidiary): to evaluate if transient elastograghy could…
- Trial name
- NCT05894993
- Testing
- transient elastograghy
- Volunteers
- 50 people
- Sponsor
- Amany Khaled Ali Ahmed
NAFLD, Diabete Type 2
The Improvement Effect of Henggliejin on Fatty Liver in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver:
To evaluate the effect and safety of Henggliejin on fatty liver in type 2 diabetes patients with nonalcoholic fatty liver disease
- Trial name
- NCT07198516
- Testing
- Addition of Hengge Liejing treatment for 48 weeks
- Volunteers
- 149 people
- Sponsor
- Fujian Medical University Union Hospital
Non-alcoholic Fatty Liver Disease
Prospective Cohort Study in Patients With NAFLD
To assess the importance of intracellular signalling pathways and its deregulation in adiposity and diabetes-related insulin resistance, liver tissue samples of patients suffering from non-alcoholic fatty liver disease (NAFLD)…
- Trial name
- NCT00575133
- Where
- Switzerland
- Volunteers
- 150 people
- Sponsor
- University of Zurich
Cirrhosis, Portal Hypertension
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Endothelin is a human hormone which has been associated with increased portal pressure in patients with liver cirrhosis (also called portal hypertension). Ambrisentan blocks the effects of endothelin.
- Conditions
- Cirrhosis, Portal Hypertension, Ascites
- Trial name
- NCT03827200
- Testing
- Ambrisentan
- Where
- 6 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Noorik Biopharmaceuticals AG
Nonalcoholic Steatohepatitis
Dapagliflozin Efficacy and Action in NASH
This is a multicentre, randomized, placebo-controlled trial to assess the efficacy and safety of dapagliflozin on improving non-alcoholic steatohepatitis as determined by liver biopsies and metabolic risk factors.
- Trial name
- DEAN (NCT03723252)
- Testing
- Dapagliflozin
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Non-alcoholic Fatty Liver Disease (NAFLD), NASH - Nonalcoholic Steatohepatitis
Integrated Phenotyping of the Gut-plAtelet-Liver AXIS in the Progression of Chronic Liver Disease (iGAL-AXIS)
Objective of the study Our working hypothesis is that platelets activated by gut-derived metabolites dock in the liver of NAFLD patients and amplify the inflammatory state by releasing pro-inflammatory cytokines/chemokines, which…
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Control Condition
- Trial name
- NCT06623084
- Testing
- Platelets characterization
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Stefania Basili
Diabetes Mellitus, Type 2, Hypertriglyceridemia
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
The design of the Phase 2 clinical trial includes the following elements: Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs.
- Conditions
- Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT05464784
- Testing
- MN-001
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- MediciNova
Non-alcoholic Fatty Liver Disease
Obesity and Nonalcoholic Fatty Liver Disease
The primary goal of this study is to provide a better understanding of: 1) the pathogenesis and pathophysiology of non-alcoholic fatty liver disease (NAFLD) in obese subjects, and 2) the effect of marked weight loss on the…
- Trial name
- NCT00262964
- Testing
- Niacin, fenofibrate
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Washington University School of Medicine
Women's Health, Hybrid Training
Hybrid Training and Middle Age
Modern living and physical inactivity results in many ailments, including obesity, non-alcoholic fatty liver disease (NAFLD), and inflammatory issues.
- Conditions
- Women's Health, Hybrid Training, Middle Aged, Non-alcoholic Fatty Liver Disease
- Trial name
- NCT05231564
- Testing
- hybrid training
- Where
- Iran
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Sistan and Baluchestan
Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases
NAFLD Among Patients With Type 2 Diabetes and CKD
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in developed countries affecting approximately 30 % of the general adult population.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Chronic Kidney Diseases, Type2 Diabetes
- Trial name
- NCT03826381
- Testing
- Magnetic resonance (MR) spectroscopy of the liver, Fibroscan, Continuous glucose monitoring (CGM) for four days.
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Liver Disease
Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis
Non-alcoholic steatohepatitis represents 10 - 15% total cases of hepatic cirrhosis. In the upcoming years, the economic burden of this disease will increase and will mean an important problem for our health system due to obesity…
- Trial name
- NCT01650181
- Testing
- Metformin, Siliphos+ Selenium - Methionine + Alpha Lipoic Acid
- Where
- Mexico
- Volunteers
- 50 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.